Trodelvy® Improved Development-Free Survival by 34% in Closely Pre-Handled HR+/HER2- Metastatic Breast Most cancers Sufferers

– At One 12 months, 3X as Many Sufferers Have been Development-Free In comparison with Physicians’ Alternative of Chemotherapy in Part 3 TROPiCS-02 Research –

– At The First Interim Evaluation, Total Survival Demonstrated a Constructive Pattern, Sufferers Will Proceed to be Adopted –

– Evaluation of Affected person-Reported Outcomes Exhibits Trodelvy Additionally Improved High quality of Life over Physicians’ Alternative of Chemotherapy –

CHICAGO–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) as we speak introduced constructive outcomes from the first evaluation of the Part 3 TROPiCS-02 examine of Trodelvy^® (sacituzumab govitecan-hziy) versus physicians’ selection of chemotherapy (TPC) in closely pre-treated HR+/HER2- metastatic breast most cancers sufferers who acquired prior endocrine remedy, CDK4/6 inhibitors and two to 4 traces of chemotherapy. The examine met its major endpoint of progression-free survival (PFS) with a statistically vital and clinically significant 34% discount within the threat of illness development or loss of life (median PFS 5.5 vs. 4 months; HR: 0.66; 95% CI: 0.53-0.83; P<0.0003). The primary interim evaluation of the important thing secondary endpoint of general survival (OS) demonstrated a development in enchancment. These information are immature, and sufferers can be adopted for subsequent OS evaluation. These findings can be featured in each a press briefing and an oral session (Summary #LBA1001) on Saturday, June 4, in the course of the 2022 American Society of Medical Oncology (ASCO) Annual Assembly.

The examine demonstrated that on the one-year mark, 3 times as many sufferers have been progression-free when handled with Trodelvy in comparison with those that acquired TPC (21% versus 7%). Enhancements in PFS with Trodelvy have been additionally constant throughout key affected person subgroups, together with sufferers who had beforehand acquired three or extra chemotherapy regimens for metastatic illness (HR: 0.70; CI: 0.52-0.95), sufferers with visceral metastasis (HR: 0.66; CI: 0.53-0.83), and the aged (≥65 years of age; HR: 0.59; CI: 0.38-0.93).

“For sufferers with HR+/HER2- metastatic breast most cancers, resistance to endocrine remedy is inevitable in virtually all instances. The usual of care is then restricted to sequential single agent chemotherapy, with declining response charges, illness management and high quality of life,” stated Dr. Hope Rugo, Professor of Medication and Director, Breast Oncology and Medical Trials Training on the College of California San Francisco Complete Most cancers Middle, U.S. “In TROPiCS-02, we enrolled closely pre-treated sufferers with metastatic breast most cancers who had illness development following a number of traces of chemotherapy. To watch a clinically significant discount within the threat of illness development or loss of life in these sufferers with restricted therapy choices is outstanding. Sacituzumab govitecan-hziy can be an necessary potential future therapy choice for these sufferers.”

A prespecified high quality of life (QoL) evaluation, one of many secondary endpoints utilizing the EORTC QLQ-C30 instrument, additionally favored Trodelvy over TPC demonstrating significant profit. Within the evaluable inhabitants, enhancements in world well being standing and fatigue with Trodelvy (n=234) in contrast with those that acquired TPC (n=207) have been additionally noticed.

“With Trodelvy, our daring ambition is that it’ll assist rework look after individuals dwelling with most cancers, together with in pre-treated HR+/HER2- metastatic breast most cancers, the place extra choices are wanted,” stated Invoice Grossman, MD, PhD, Senior Vice President, Therapeutic Space Head, Gilead Oncology. “We sit up for persevering with discussions with regulatory companies to additional perceive how Trodelvy can affect this affected person inhabitants with a excessive unmet want.”

The security profile for Trodelvy was in keeping with prior research, with no new security issues recognized on this affected person inhabitants. Essentially the most frequent Grade ≥3 treatment-related hostile reactions for Trodelvy in comparison with TPC have been neutropenia (51% versus 38%), diarrhea (9% versus 1%), leukopenia (9% versus 5%), anemia (6% versus 3%), fatigue (6% versus 2%) and febrile neutropenia (5% versus 4%).

Trodelvy has not been authorized by any regulatory company for the therapy of HR+/HER2- metastatic breast most cancers. Its security and efficacy haven’t been established for this indication. Trodelvy has a Boxed Warning for extreme or life-threatening neutropenia and extreme diarrhea; please see under for extra Essential Security Info.

About HR+/HER2- Metastatic Breast Most cancers

Hormone receptor-positive/human epidermal development issue receptor 2-negative (HR+/HER2-) breast most cancers is the commonest kind of breast most cancers and accounts for about 70% of all new instances, or almost 400,000 diagnoses worldwide every year. Nearly one in three instances of early-stage breast most cancers finally change into metastatic, and amongst sufferers with HR+/HER2- metastatic illness, the five-year relative survival fee is 30%. As sufferers with HR+/HER2- metastatic breast most cancers change into immune to endocrine-based remedy, their major therapy choice is restricted to single-agent chemotherapy. On this setting, it is not uncommon to obtain a number of traces of chemotherapy regimens over the course of therapy, and the prognosis stays poor.

Concerning the TROPiCS-02 Research

The TROPiCS-02 examine is a world, multicenter, open-label, Part 3 examine, randomized 1:1 to judge Trodelvy versus physicians’ selection of chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine) in 543 sufferers with HR+/HER2- metastatic breast most cancers who have been beforehand handled with endocrine remedy, CDK4/6 inhibitors and two to 4 traces of chemotherapy for metastatic illness. The first endpoint is progression-free survival per Response Analysis Standards in Strong Tumors (RECIST 1.1) as assessed by blinded impartial central assessment (BICR) for members handled with Trodelvy in comparison with these handled with chemotherapy. Secondary endpoints embrace general survival, general response fee, scientific profit fee and period of response, in addition to evaluation of security and tolerability and high quality of life measures. Within the examine, HER2 negativity was outlined per American Society of Medical Oncology (ASCO) and the Faculty of American Pathologists (CAP) standards as immunohistochemistry (IHC) rating of 0, IHC 1+ or IHC 2+ with a unfavourable in-situ hybridization (ISH) take a look at. Extra details about TROPiCS-02 is obtainable at https://clinicaltrials.gov/ct2/present/NCT03901339.

About Trodelvy

Trodelvy^® (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate. Trop-2 is a cell floor antigen extremely expressed in a number of tumor sorts, together with in additional than 90% of breast and bladder cancers. Trodelvy is deliberately designed with a proprietary hydrolyzable linker hooked up to SN-38, a topoisomerase I inhibitor payload. This distinctive mixture delivers potent exercise to each Trop-2 expressing cells and the microenvironment.

Trodelvy is authorized in additional than 35 nations, with a number of extra regulatory critiques underway worldwide, for the therapy of grownup sufferers with unresectable domestically superior or metastatic triple-negative breast most cancers (TNBC) who’ve acquired two or extra prior systemic therapies, no less than one among them for metastatic illness. Trodelvy can be authorized within the U.S. underneath the accelerated approval pathway for the therapy of grownup sufferers with domestically superior or metastatic urothelial most cancers (UC) who’ve beforehand acquired a platinum-containing chemotherapy and both programmed loss of life receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

Trodelvy can be being developed for potential investigational use in different TNBC and metastatic UC populations, in addition to a spread of tumor sorts the place Trop-2 is extremely expressed, together with hormone receptor-positive/human epidermal development issue receptor 2-negative (HR+/HER2-) metastatic breast most cancers, metastatic non-small cell lung most cancers (NSCLC), metastatic small cell lung most cancers (SCLC), head and neck most cancers, and endometrial most cancers.

U.S. Indication for Trodelvy

In america, Trodelvy is indicated for the therapy of:

• Grownup sufferers with unresectable domestically superior or metastatic TNBC who’ve acquired two or extra prior systemic therapies, no less than one among them for metastatic illness.
• Grownup sufferers with domestically superior or metastatic UC who’ve beforehand acquired a platinum-containing chemotherapy and both programmed loss of life receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. This indication is authorized underneath accelerated approval based mostly on tumor response fee and period of response. Continued approval for this indication could also be contingent upon verification and outline of scientific profit in a confirmatory trial.

U.S. Essential Security Info for Trodelvy

BOXED WARNING: NEUTROPENIA AND DIARRHEA

• Extreme or life-threatening neutropenia could happen. Withhold Trodelvy for absolute neutrophil depend under 1500/mm³ or neutropenic fever. Monitor blood cell counts periodically throughout therapy. Contemplate G-CSF for secondary prophylaxis. Provoke anti-infective therapy in sufferers with febrile neutropenia at once.
• Extreme diarrhea could happen. Monitor sufferers with diarrhea and provides fluid and electrolytes as wanted. Administer atropine, if not contraindicated, for early diarrhea of any severity. On the onset of late diarrhea, consider for infectious causes and, if unfavourable, promptly provoke loperamide. If extreme diarrhea happens, withhold Trodelvy till resolved to ≤Grade 1 and cut back subsequent doses.

CONTRAINDICATIONS

• Extreme hypersensitivity response to Trodelvy.

WARNINGS AND PRECAUTIONS

Neutropenia: Extreme, life-threatening, or deadly neutropenia can happen and should require dose modification. Neutropenia occurred in 61% of sufferers handled with Trodelvy. Grade 3-4 neutropenia occurred in 47% of sufferers. Febrile neutropenia occurred in 7%. Withhold Trodelvy for absolute neutrophil depend under 1500/mm³ on Day 1 of any cycle or neutrophil depend under 1000/mm³ on Day 8 of any cycle. Withhold Trodelvy for neutropenic fever.

Diarrhea: Diarrhea occurred in 65% of all sufferers handled with Trodelvy. Grade 3-4 diarrhea occurred in 12% of sufferers. One affected person had intestinal perforation following diarrhea. Neutropenic colitis occurred in 0.5% of sufferers. Withhold Trodelvy for Grade 3-4 diarrhea and resume when resolved to ≤Grade 1. At onset, consider for infectious causes and if unfavourable, promptly provoke loperamide, 4 mg initially adopted by 2 mg with each episode of diarrhea for a most of 16 mg day by day. Discontinue loperamide 12 hours after diarrhea resolves. Further supportive measures (e.g., fluid and electrolyte substitution) might also be employed as clinically indicated. Sufferers who exhibit an extreme cholinergic response to therapy can obtain acceptable premedication (e.g., atropine) for subsequent therapies.

Hypersensitivity and Infusion-Associated Reactions: Critical hypersensitivity reactions together with life-threatening anaphylactic reactions have occurred with Trodelvy. Extreme indicators and signs included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and pores and skin reactions. Hypersensitivity reactions inside 24 hours of dosing occurred in 37% of sufferers. Grade 3-4 hypersensitivity occurred in 2% of sufferers. The incidence of hypersensitivity reactions resulting in everlasting discontinuation of Trodelvy was 0.3%. The incidence of anaphylactic reactions was 0.3%. Pre-infusion medicine is really helpful. Observe sufferers intently for hypersensitivity and infusion-related reactions throughout every infusion and for no less than half-hour after completion of every infusion. Treatment to deal with such reactions, in addition to emergency tools, needs to be accessible for instant use. Completely discontinue Trodelvy for Grade 4 infusion-related reactions.

Nausea and Vomiting: Nausea occurred in 66% of all sufferers handled with Trodelvy and Grade 3 nausea occurred in 4% of those sufferers. Vomiting occurred in 39% of sufferers and Grade 3-4 vomiting occurred in 3% of those sufferers. Premedicate with a two or three drug mixture routine (e.g., dexamethasone with both a 5-HT3 receptor antagonist or an NK1 receptor antagonist in addition to different medication as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV). Withhold Trodelvy doses for Grade 3 nausea or Grade 3-4 vomiting and resume with extra supportive measures when resolved to Grade ≤1. Further antiemetics and different supportive measures might also be employed as clinically indicated. All sufferers needs to be given take-home medicines with clear directions for prevention and therapy of nausea and vomiting.

Elevated Threat of Antagonistic Reactions in Sufferers with Diminished UGT1A1 Exercise: Sufferers homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at elevated threat for neutropenia, febrile neutropenia, and anemia and could also be at elevated threat for different hostile reactions with Trodelvy. The incidence of Grade 3-4 neutropenia was 67% in sufferers homozygous for the UGT1A1*28, 46% in sufferers heterozygous for the UGT1A1*28 allele and 46% in sufferers homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 25% in sufferers homozygous for the UGT1A1*28 allele, 10% in sufferers heterozygous for the UGT1A1*28 allele, and 11% in sufferers homozygous for the wild-type allele. Carefully monitor sufferers with recognized lowered UGT1A1 exercise for hostile reactions. Withhold or completely discontinue Trodelvy based mostly on scientific evaluation of the onset, period and severity of the noticed hostile reactions in sufferers with proof of acute early-onset or unusually extreme hostile reactions, which can point out lowered UGT1A1 perform.

Embryo-Fetal Toxicity: Primarily based on its mechanism of motion, Trodelvy could cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant lady. Trodelvy incorporates a genotoxic part, SN-38, and targets quickly dividing cells. Advise pregnant girls and females of reproductive potential of the potential threat to a fetus. Advise females of reproductive potential to make use of efficient contraception throughout therapy with Trodelvy and for six months after the final dose. Advise male sufferers with feminine companions of reproductive potential to make use of efficient contraception throughout therapy with Trodelvy and for 3 months after the final dose.

ADVERSE REACTIONS

Within the ASCENT examine (IMMU-132-05), the commonest hostile reactions (incidence ≥25%) have been fatigue, neutropenia, diarrhea, nausea, alopecia, anemia, constipation, vomiting, stomach ache, and decreased urge for food. Essentially the most frequent critical hostile reactions (SAR) (>1%) have been neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR have been reported in 27% of sufferers, and 5% discontinued remedy on account of hostile reactions. The commonest Grade 3-4 lab abnormalities (incidence ≥25%) within the ASCENT examine have been lowered neutrophils, leukocytes, and lymphocytes.

Within the TROPHY examine (IMMU-132-06), the commonest hostile reactions (incidence ≥25%) have been diarrhea, fatigue, neutropenia, nausea, any an infection, alopecia, anemia, decreased urge for food, constipation, vomiting, stomach ache, and rash. Essentially the most frequent critical hostile reactions (SAR) (≥5%) have been an infection (18%), neutropenia (12%, together with febrile neutropenia in 10%), acute kidney damage (6%), urinary tract an infection (6%), and sepsis or bacteremia (5%). SAR have been reported in 44% of sufferers, and 10% discontinued on account of hostile reactions. The commonest Grade 3-4 lab abnormalities (incidence ≥25%) within the TROPHY examine have been lowered neutrophils, leukocytes, and lymphocytes.

DRUG INTERACTIONS

UGT1A1 Inhibitors: Concomitant administration of Trodelvy with inhibitors of UGT1A1 could enhance the incidence of hostile reactions on account of potential enhance in systemic publicity to SN-38. Keep away from administering UGT1A1 inhibitors with Trodelvy.

UGT1A1 Inducers: Publicity to SN-38 could also be considerably lowered in sufferers concomitantly receiving UGT1A1 enzyme inducers. Keep away from administering UGT1A1 inducers with Trodelvy.

Please see full Prescribing Info, together with BOXED WARNING.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical firm that has pursued and achieved breakthroughs in drugs for greater than three a long time, with the purpose of making a more healthy world for all individuals. The corporate is dedicated to advancing progressive medicines to forestall and deal with life-threatening ailments, together with HIV, viral hepatitis and most cancers. Gilead operates in additional than 35 nations worldwide, with headquarters in Foster Metropolis, California.

Ahead-Wanting Statements

This press launch contains forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995 which can be topic to dangers, uncertainties and different components, together with Gilead’s skill to provoke, progress or full scientific trials involving Trodelvy inside presently anticipated timelines or in any respect; the potential of unfavorable outcomes from ongoing or extra scientific trials involving Trodelvy; uncertainties regarding regulatory functions for Trodelvy and associated submitting and approval timelines, together with for the therapy of HR+/HER2- breast most cancers, metastatic TNBC, mUC, NSCLC, SCLC, head and neck most cancers, and endometrial most cancers, within the presently anticipated timelines or in any respect; Gilead’s skill to obtain regulatory approvals for such indications in a well timed method or in any respect, and the danger that any such approvals could also be topic to vital limitations on use; the chance that Gilead could make a strategic resolution to discontinue improvement of Trodelvy for such indications and because of this, Trodelvy could by no means be commercialized for these indications; and any assumptions underlying any of the foregoing. These and different dangers, uncertainties and different components are described intimately in Gilead’s Quarterly Report on Type 10-Q for the quarter ended March 31, 2022, as filed with the U.S. Securities and Trade Fee. These dangers, uncertainties and different components might trigger precise outcomes to vary materially from these referred to within the forward-looking statements. All statements aside from statements of historic reality are statements that may very well be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements aren’t ensures of future efficiency and contain dangers and uncertainties, and is cautioned to not place undue reliance on these forward-looking statements. All forward-looking statements are based mostly on data presently accessible to Gilead, and Gilead assumes no obligation and disclaims any intent to replace any such forward-looking statements.

U.S. Prescribing Info for Trodelvy together with BOXED WARNING, is obtainable at www.gilead.com.

Trodelvy, Gilead and the Gilead emblem are logos of Gilead Sciences, Inc., or its associated corporations.

For extra details about Gilead, please go to the corporate’s web site at www.gilead.com, comply with Gilead on Twitter (@GileadSciences) or name Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Jacquie Ross, Traders

[email protected]

Nathan Kaiser, U.S. Media

[email protected]

Karley Ura, World Media

[email protected]